



Company Presentation

Planet Microcap Conference Las Vegas – June 17, 2026

Forward Looking Statements

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies, Inc. (the “Company”, “us” or “we”) with respect to anticipated future performance. Words such as “expects,” “anticipates,” “intends,” “plans,” “likely,” “will,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore such statements included in this presentation may not prove to be accurate. Forward-looking statements in this presentation relate to our: ongoing commitment to deliver advance wound care solutions to improve the quality of life for patients; expectations regarding growth and the related driving factors; expectations regarding commercialization and opportunities in hospital-based sites of services; expectations regarding the performance of direct sales representatives and independent sales agents; expectations regarding the assignment or transfer of key GPO contracts; expectations regarding the innovation of new placental platform technologies and complementary modalities; expectations regarding intellectual property values and uses; estimates and expectations regarding the total addressable wound market; strategic growth initiatives, including but not limited to strategic acquisitions, expansion into new markets and expansion of our commercial team; expectations regarding further penetration of current markets; the opportunity for leverage on sales and marketing expenses; ability to capitalize and report clinically significant data over our competitors; and expectations regarding future operations, financial positions, estimated revenue, forecasts, prospects and plans; expectations regarding the timing of completion of the 2024 and 2025 audits; and expectations regarding our plans to uplist to the Nasdaq Capital Market.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. The following is a list of risks, among others, that could cause actual results to differ materially from those contemplated by the forward-looking statements: the risk that the Company may not be able to achieve or maintain profitability in the future; the risk that the Company has derived the majority of our revenue from a distribution agreement; the risk that a material amount of revenues and accounts receivable are concentrated in one or more customers, and that if the Company loses or experiences a significant reduction in sales, the Company’s revenues may decrease substantially and materially affect the Company’s results of operations and financial condition; the audit of the Company’s restated financial statements and the impact of any changes to the accounting treatment of the Company’s revenue and expenses; significant and continuing competition, which could adversely affect the Company’s business, results or operations and financial condition; the Company’s ability to achieve its strategic and financial objectives depends in part on the successful integration of newly acquired assets and the continued effectiveness of its commercial organization; the Company has incurred significant losses since inception and may incur losses in the future; and the impact of any changes to the reimbursement levels for the Company’s products; challenges associated with integrating new products, technologies, or operational capabilities—including unanticipated costs, delays, or resource demands—could adversely affect expected synergies, operational performance, and long-term value creation. In addition, the Company’s performance remains dependent on the sustained productivity and effectiveness of its salesforce. Any inability to recruit, retain, train, or motivate sales personnel, or disruptions that negatively impact sales execution, could impair revenue growth and hinder the successful commercialization of current and future assets; the risk that the Company will be unable to maintain its use of intellectual property; the Company’s ability to convince physicians that the products are safe and effective alternatives to existing treatments and that the Company’s products should be used in their procedures; the risk that the Company may be unable to successfully market its products to the end users of such products; the risk that the Company will be unable to maintain adequate levels of reimbursement from public and private insurers and health systems which may result in changes to the ways in which the Company’s products are reimbursed in various sites of service and, as a result may adversely impact the Company’s financial results; the risk that the Company will be unable to produce sufficient data to support coverage of our products under the finalized LCDs or otherwise satisfy any regulatory requirements needed to ensure our products are eligible for Medicare reimbursement; the risk that the FDA may in the future determine that certain products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the Public Health Service Act, and may require that the Company revise its labeling and marketing claims for these products or require the Company to suspend sales of such products until FDA pre-market clearance or approval is obtained, either of which could adversely affect the Company’s business, results of operations, and financial condition; the risk that the rate of reimbursement and coverage for the purchase of the Company’s products by government and private insurance may change; the impact of any changes in applicable laws or regulations; and the risk that the Company may not meet the listing standards of the Nasdaq Stock Market.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Our Mission

To **create** and **deliver** the most
advanced wound healing
technologies in the **world**

*In **Relentless Pursuit** of Healing*

BioStem Snap Shot

Corporate Profile

- Ticker: BSEM
- Headquarters: Pompano Beach, FL
- Share Price: \$4.15
- Market Cap: \$72 million
- Shares Outstanding: 16.9 million, ~20 million (Fully Diluted)

Recent Financials

- 1Q26 Revenue: \$6.1 million
- 1Q26 Gross Margin: 61%
- 1Q26 Cash and Cash Equivalents: \$13.7 million
- FY26 Top Line Revenue Guidance \$25-\$29mm

Key Corporate Developments

● **BioTissue Acquisition**

- Closed acquisition of BioTissue surgical and wound care business and progressed integration initiatives including reassignment of all GPO contracts, and expansion of direct sales force

● **Progression on Pathway to Uplisting**

- Completion and publication of 2024 and 2025 audited financial statements by KPMG
- Confidentially filed Form 10, currently in comment period
- Nasdaq application filed

● **Received Analyst Coverage**

- Coverage initiated by Swayampakula Ramakanth at HCW with a price target of \$7

● **Strengthening of Balance Sheet**

- Retired outstanding debt with GMA to resolve two existing promissory notes
- Closed \$2.5 PIPE with institutional investor

● **Expanded Leadership Team/Board**

- Appointment of Katherine Gorrell, Chief Legal and Compliance Officer
- Appointment of 3 new board members including Rayna Lesser Hannaway, ex-Fidelity Small Cap PM

The Need for Perinatal Allografts vs SOC

*Regenerative medicine promotes faster healing and reduces complications**

Patient Impact¹



- ~155,000 lower limb amputations annually
- ~800,000 DFU hospitalizations annually

Economic Impact²



Infections and complications cost the health system an estimated \$30B+ each year

Faster Healing

Perinatal allografts optimize the healing environment, accelerating tissue regeneration

Minimize Scarring & Adhesion

Regenerative healing reduces scarring and adhesion formation, ensuring a faster return to normal activity

Infection Prevention

Sterile, timely care prevents infections, which can lead to costly complications like sepsis

Pain Management

Controlling inflammation reduces patient discomfort

Reduced Complications

Effective management reduces the risk of chronic non-healing wounds and postoperative complications

Large and Underserved ~\$23B US Soft Tissue Allograft Opportunity

Driving adoption of perinatal tissue allografts for multiple market segments

1 Orthopedics/Sports Medicine

US TAM: ~\$2.3B

Knee Osteoarthritis | Soft Tissue Repair | Trauma

2 Chronic Wound Care


US TAM: ~\$15B

DLU | VLU | Pressure Ulcers | Pilonidal Cyst | Hidradenitis Suppurativa

3 Foot & Ankle

US TAM: ~\$1.1B

Tendon Repair | Joint Replacement & Reconstruction | Trauma



4 Urology/ Colorectal

US TAM: ~\$1.5B

Radical Prostatectomy | Urethral / Ureteral Strictures | Reconstruction

5 Spine

US TAM: ~\$1.6B

Facet Joint Pain | Hardware Adhesion Barrier

6 Women's Health

US TAM: ~\$1.8B

Pelvic Floor Recon | Myomectomy | Hysterectomy | Ovarian Cystectomy

BioStem Snapshot

Well positioned for market expansion and growth

Differentiated Technology	Strong Foundation
3 Industry-Leading Technologies BioRetain®, CryoTek® and SteriTek® all demonstrate superiority when compared to the market leading products	Experienced National Sales Force > 25 direct reps and >30 independent agents plus GPO contracts
6 Perinatal-Derived Allograft Brands Including our newly acquired Neox® and Clarix® portfolios	Expanded Addressable Market End markets now include surgical applications in facility settings, including commercially insured population
Industry-Leading IP Portfolio 68 issued U.S. patents and 81 pending	Unparalleled Technical Data 400+ publications across all technologies and products
Pipeline: 510(k) Micronized Product 510(k) clearance pending for Flo-based product	World-Class Manufacturing Capabilities Experienced in-house manufacturing with ability to scale and produce historically industry leading margins

Our Regenerative Medicine Solutions

A complete portfolio of perinatal tissue allografts

NON-WOUND / SURGICAL

Orthopedics/Sports Medicine · Foot & Ankle · Urology / Colorectal · Spine · Women's Health

Clarix 1K

Cryopreserved amnion and UTA allograft

SOURCE	THICKNESS
Amnion & UTA	1,000 µm
MAX SIZE	STORAGE
8.0 × 3.0 cm	❄️ Freezer

Clarix 100

Cryopreserved amnion allograft

SOURCE	THICKNESS
Amnion Only	100 µm
MAX SIZE	STORAGE
7.0 × 7.0 cm	❄️ Freezer

Clarix Flo

Particulate amnion and UTA allograft

SOURCE	THICKNESS
Amnion & UTA	N/A
MAX SIZE	STORAGE
N/A	🧊 Room Temp

WOUND

Chronic Wound Care

Neox 1K

Cryopreserved amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	1,000 µm
MAX SIZE	STORAGE
8.0 × 3.0 cm	❄️ Freezer

Neox 100

Cryopreserved amnion wound allograft

SOURCE	THICKNESS
Amnion Only	100 µm
MAX SIZE	STORAGE
7.0 × 7.0 cm	❄️ Freezer

Neox RT

Cryopreserved amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	~600 µm
MAX SIZE	STORAGE
8.0 × 3.0 cm	🧊 Room Temp

Neox Flo

Particulate amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	N/A
MAX SIZE	STORAGE
N/A	🧊 Room Temp

VENDAJE

Dehydrated human amniotic membrane allograft

SOURCE	THICKNESS
Amnion + Int.	100 µm
MAX SIZE	STORAGE
10.0 × 20.0 cm	🧊 Room Temp

VENDAJE AC

Dehydrated amniotic membrane — amnion, int. chorion

SOURCE	THICKNESS
Amnion, Int., Chorion	N/A
MAX SIZE	STORAGE
10.0 × 20.0 cm	🧊 Room Temp

Products added from acquisition of BioTissue surgical and wound assets

BioStem




UTA – ultra-thick amniotic membrane

Expanded Payor Mix Towards Commercial Reimbursement

BioTissue acquisition opens up the larger Hospital market with favorable coverage and economics


***Physician Office
Market***
Vendaje




BioTissue Acquisition



***Hospital
Market***
Neox, Clarix



Multiple Commercial Growth Levers



**EXPAND DIRECT SALES TEAM TO
40+ BY YEAR-END**

**DRIVE ADOPTION WITH
PEER-to-PEER SELLING**

**INCREASE PAYOR COVERAGE
AND PATIENT ACCESS**

EXECUTING PRODUCT ROAD MAP

Results of DFU and Ambulate Studies

Multiple robust randomized control trials demonstrate clinical efficacy

Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers¹

- Trial designed to meet the most **rigorous patient selection and clinical endpoint** standards
 - BR-AC achieved **superior clinical outcomes** in this patient population
 - The **probability of healing** in the BR-AC arm was **53%** while the probability of healing in the standard of care arm was **31%**
- In a competitive study, the BR-AC arm required **2.7 fewer applications** and **9.1 less treatment days** for closure compared to the market leader

Ambulate Study²

- Trial design to treat the most **severe chronic wounds** – Wagner Grade III/IV
- **66% closure** at 26 weeks
- Average **1.67±0.87 applications** to achieve closure
- **High healing rate** for complex DFUs that are often excluded from clinical trials

World-Class Manufacturing

AATB® accredited, cGTP facility

State of the art, vertically integrated manufacturing facility

Currently processing 30k sq cm monthly

Capacity up to 100K sq cm monthly to support future growth

6,100 sq ft dedicated area; 3,000 sq ft ISO clean room space

Located in Pompano Beach, FL

Utilizing a supply agreement with BioTissue for Neox/Clarix products for 12+ months; technology transfer in-house will improve gross margin



Management Team

Accomplished team with deep industry experience



Jason Matuszewski LSSBB
Chief Executive Officer



Andrew Van Vurst CTBS
Chief Operating Officer



Brandon Poe
Chief Financial Officer



Michael Fortunato CPA
Chief Accounting Officer



Barry Hassett
Chief Commercial Officer



Katherine Gorrell
Chief Legal and Compliance Officer



Wendy Weston PhD, CTBS
Vice President, R&D



Noah Agron
Vice President, Corporate Finance & Strategy



Lita Lilly
Vice President of Sales



Grace Tran
Director of Lab Operations



Taylor Sabol
Director of Quality



Michael Milberg
Government Affairs



Nick McCoy
Clinical Operations



Financial/Capital Markets Outlook

Strong Financial Profile

- Investing for growth in our surgical revenue base; Acquired assets generated \$29M in 2025 and largely unaffected by CMS price changes
- Transition period for wound business in 1H 2026 as market digests CMS payment changes
- Efficient manufacturing process (and the future technology transfer of acquired assets) will continue to deliver healthy gross margins*
- Track record of delivering positive Adjusted EBITDA and cashflow
- \$13.7M cash balance as of March 31, 2026

Uplist to Nasdaq

- Completed 2024 and 2025 audits, enabling pursuit of uplisting
- Confidentially filed Form 10
- Started Nasdaq application

2026 Catalyst Roadmap

Building momentum through integration, expansion, and value creation

Successful integration

- Maintain acquired team, customer and revenue
- Reassign GPO agreements
- Build commercial infrastructure for growth



Uplist to Nasdaq

- Complete the financial audit with KPMG
- File with SEC to uplist to Nasdaq



Sales expansion

- Expand direct Sales team to 40+ by year-end
- Add ISA coverage in open territories

Launch new products

- Add BioRetain portfolio to GPOs
- Launch 510K cleared product - Catalyze

Clinical Evidence

- Publish definitive DFU analysis
- Publish top line VLU data
- Use data for evidence-based selling

Financial

- Deliver Revenue growth in 2H 2026
- Prepare for Technology transfer of Neox and Clarix to improve gross margin
- Improve Operating Margins across the year



Thank you